SCHEMBL2035522

SCHEMBL2035522

C[C@@H](Oc1cccc(F)c1F)c1ccnc(N)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.58
HTR1A P08908 3/20 0.48
DRD2 P14416 3/20 0.48
HTR2A P28223 3/20 0.48
HTR7 P34969 3/20 0.48
HTR6 P50406 3/20 0.48
HRH4 Q9H3N8 3/20 0.39
MET P08581 1/20 0.38
GRM4 Q14833 1/20 0.36
KDM4E B2RXH2 3/20 0.36
RAB9A P51151 3/20 0.36
ALDH1A1 P00352 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
TRPA1 O75762 1/20 0.35
MAPK14 Q16539 1/20 0.35
DHFR P00374 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2035524 1.00 POLB (0.58) POLBHTR1ADRD2HTR2AHTR7
SCHEMBL2037273 0.81 POLB (0.61) POLBHTR1ADRD2HTR2AHTR7
SCHEMBL2037137 0.81 POLB (0.61) POLBHTR1ADRD2HTR2AHTR7
SCHEMBL2040896 0.81 POLB (0.61) POLBHTR1ADRD2HTR2AHTR7
SCHEMBL2037270 0.81 POLB (0.61) POLBHTR1ADRD2HTR2AHTR7
SCHEMBL2037138 0.81 POLB (0.61) POLBHTR1ADRD2HTR2AHTR7
SCHEMBL2035785 0.78 POLB (0.71) POLBHTR1ADRD2HTR2AHTR7
SCHEMBL2035787 0.78 POLB (0.71) POLBHTR1ADRD2HTR2AHTR7
SCHEMBL13277595 0.77 POLB (0.60) POLBHTR1ADRD2HTR2AHTR7
SCHEMBL2033835 0.77 POLB (0.60) POLBHTR1ADRD2HTR2AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2516397-B1 Amino-heteroaryl derivatives as HCN blockers MERCK SHARP & DOHME (NL) 2016-07-13 EP disclosed
US-8952001-B2 Amino-heteroaryl derivatives as HCN blockers MERCK SHARP & DOHME CORP. (US) 2015-02-10 US disclosed
EP-2516397-A1 AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS MSD Oss B.V. (NL) 2012-10-31 EP disclosed
US-20120264728-A1 AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS ORGANON BIOSCIENCES NEDERLAND B.V. (NL) 2012-10-18 US disclosed
WO-2011076723-A1 AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS N.V. ORGANON (NL) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120264728-A1 AMINO-HETEROARYL DERIVATIVES AS HCN BLOCKERS HCN1, HCN3, HCN2 POLB 3931/4885HTR1A 280/4885DRD2 1315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.